Efectividad y seguridad de la «triple antiagregación» en pacientes sometidos a intervencionismo coronario

Latour-Pérez, Jaime; de-Miguel-Balsa, Eva; Alcalá-López, Adoración; Coves-Orts, F.J.

doi:10.1016/s0210-5691(07)74814-3

Cited by 4 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, the available studies that analyze the cost‐effectiveness of GPIIb/IIIa inhibitors in NSTE‐ACS patients rely on placebo‐controlled clinical trials [10,19,37–40], which do not inform about the incremental benefits and risks of GPIIb/IIIa inhibitors. Fortunately, some recent studies provide adequate evidence on the efficacy and safety of triple antiplatelet therapy in these patients [8,9]. This evidence allows the assessment of the efficiency of this therapy in patients already treated with clopidogrel.…”

Section: Discussionmentioning

confidence: 99%

“…The main source of evidence about the comparative effectiveness and safety of triple versus double antiplatelet therapy was a recent systematic review and meta‐analysis [9] based on nine randomized controlled trials. According to this review, the addition of GPIIb/IIIa inhibitors reduced the risk of death or myocardial infarction at 30 days in those trials that included patients with NSTE‐ACS (relative risk [RR] 0.67; 95% confidence interval [CI] 0.56–0.80) but not in studies that excluded NSTE‐ACS patients (RR 1.07; 95% CI 0.75–1.53) ( P ‐test of interaction 0.0175).…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, consensus among the authors was used when appropriate. The sources of data about the effectiveness, costs and utilities are summarized in Tables 1-3 [1, 7,[9][10][11][12][15][16][17][18][19][20][21][22][23][24][25][26].…”

Section: Data Inputs (Tables 1-3)mentioning

confidence: 99%

“…Recently, several studies have provided new evidence on the benefits and risks of using GPIIb/IIIa inhibitors in patients pretreated with clopidogrel [8,9], whereas other studies have added important information on the comparative advantages of selective and upstream strategies [10,11]. Therefore, a new economic evaluation of the use of GPIIb/IIIa inhibitors under current clinical conditions, which combines the most recent clinical and economic studies, is justified.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Data Inputs (Tables 1-3)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Este triple tratamiento antiagregante se ha mostrado como beneficioso en múltiples estudios [44][45][46][47] (clase: IIB/NE: B).…”

Section: Prasugrelunclassified

Recomendaciones para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST

et al. 2010

View full text Add to dashboard Cite

These recommendations are designed to be of assistance to doctors in ICUs when making first evaluations of these patients. They are mainly intended to assist with early diagnosis, risk stratification and initial treatment. The need for individualised treatment is at present one of the main objectives in the management of Acute Coronary Syndrome (ACS), with or without ST elevation, and this is why we believe the recommendations should be of a predominantly practical nature, given that they affect decision making in the day to day practice of medicine.

show abstract

Oral Antiplatelet Therapy in Coronary Disease

Gonçalves

Falcão

2017

American Journal of Therapeutics

View full text Add to dashboard Cite

Ischemic heart disease is the major isolated cause of death worldwide, responsible for 7,249,000 deaths in 2008, 12.7% of deaths from any causes. The inhibition of platelet activation and aggregation is an important therapeutic target. Cyclooxygenase inhibitors and thienopyridines are currently the 2 most used pharmacological classes, but novel antiplatelet agents have currently an important role. The most recent thienopyridine, prasugrel, allows an irreversible inhibition of the P2Y12 platelet receptor associated to a faster and more consistent onset of action rather the previous antiplatelet agents of the same class. Cyclopentyl-triazolo-pyrimidines, a newer pharmacological class from which ticagrelor is an example, also act at the P2Y12 platelet receptor, and like prasugrel, ticagrelor inhibits platelet aggregation in a fast and consistent manner, however, in a reversible way. This article aims to conduct a review on the literature about the most recent information and guidelines on oral antiplatelet agents available for the management of coronary disease.

show abstract

Efectividad y seguridad de la «triple antiagregación» en pacientes sometidos a intervencionismo coronario

Cited by 4 publications

References 22 publications

Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis

Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively: A Cost-Effectiveness Analysis

Recomendaciones para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST

Oral Antiplatelet Therapy in Coronary Disease

Contact Info

Product

Resources

About